176 related articles for article (PubMed ID: 37937865)
1. Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs.
Ramachandran S; Prakash P; Mohtar N; Kumar KS; Parumasivam T
Pharm Dev Technol; 2023 Dec; 28(10):978-991. PubMed ID: 37937865
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
3. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
6. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis.
Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK
J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
[TBL] [Abstract][Full Text] [Related]
9. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary drug delivery systems for tuberculosis treatment.
Pham DD; Fattal E; Tsapis N
Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
[TBL] [Abstract][Full Text] [Related]
11. Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis.
Chae J; Choi Y; Tanaka M; Choi J
J Biosci Bioeng; 2021 Dec; 132(6):543-551. PubMed ID: 34538591
[TBL] [Abstract][Full Text] [Related]
12. A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.
Khadka P; Dummer J; Hill PC; Katare R; Das SC
Drug Deliv Transl Res; 2023 May; 13(5):1246-1271. PubMed ID: 36131190
[TBL] [Abstract][Full Text] [Related]
13. Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies.
Viswanathan V; Pharande R; Bannalikar A; Gupta P; Gupta U; Mukne A
Drug Dev Ind Pharm; 2019 Jan; 45(1):11-20. PubMed ID: 30122088
[TBL] [Abstract][Full Text] [Related]
14. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
15. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
Sharma R; Saxena D; Dwivedi AK; Misra A
Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
[TBL] [Abstract][Full Text] [Related]
16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
17. Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies.
Alzahabi KH; Usmani O; Georgiou TK; Ryan MP; Robertson BD; Tetley TD; Porter AE
Emerg Top Life Sci; 2020 Dec; 4(6):581-600. PubMed ID: 33315067
[TBL] [Abstract][Full Text] [Related]
18. Inhaled drug delivery for tuberculosis therapy.
Muttil P; Wang C; Hickey AJ
Pharm Res; 2009 Nov; 26(11):2401-16. PubMed ID: 20183916
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
